skip navigationU S P T O SealUnited States Patent and Trademark Office AOTW logo
Home|Site Index|Search|Guides|Contacts|eBusiness|eBiz alerts|News|Help
Assignments on the Web > Patent Query
Patent Assignment Details
NOTE:Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Reel/Frame:055156/0261   Pages: 5
Recorded: 02/04/2021
Attorney Dkt #:398110-51HPUS & C1-C4
Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Total properties: 5
1
Patent #:
NONE
Issue Dt:
Application #:
17018591
Filing Dt:
09/11/2020
Publication #:
Pub Dt:
03/18/2021
Title:
HPK1 ANTAGONISTS AND USES THEREOF
2
Patent #:
Issue Dt:
08/03/2021
Application #:
17020013
Filing Dt:
09/14/2020
Publication #:
Pub Dt:
03/18/2021
Title:
SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-C]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS
3
Patent #:
Issue Dt:
06/08/2021
Application #:
17020050
Filing Dt:
09/14/2020
Publication #:
Pub Dt:
03/25/2021
Title:
SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS
4
Patent #:
Issue Dt:
06/15/2021
Application #:
17020122
Filing Dt:
09/14/2020
Publication #:
Pub Dt:
03/18/2021
Title:
SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS
5
Patent #:
Issue Dt:
06/01/2021
Application #:
17020173
Filing Dt:
09/14/2020
Publication #:
Pub Dt:
03/25/2021
Title:
SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS
Assignor
1
Exec Dt:
12/18/2020
Assignee
1
120 WEST 45TH STREET, 17TH FLOOR
NEW YORK, NEW YORK 10036
Correspondence name and address
DECHERT LLP
ONE INTERNATIONAL PLACE, 40TH FLOOR
100 OLIVER STREET
BOSTON, MA 02110-2605

Search Results as of: 06/03/2024 11:18 AM
If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified: August 25, 2017 v.2.6
| .HOME | INDEX| SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT